glp-1 treatment mandeville drugs are all approved for glucose control in type 2 diabetes (T2D). Some of them also have additional indications reflecting their demonstrated benefits for cardiovascular disease, kidney health, and obesity. None Featured GLP-1 Program 2026 |

Glucagon-like peptide-1 receptor agonists: new evidence of kidney and cardiovascular protection from the FLOW and SELECT Trials

TRIUMPH-1 is the first Phase 3 trial in retatrutides obesity programme to report results

Keeping legs mostly straight (slight knee bend) and back flat, hinge at hips, lowering dumbbells towards floor

Contact dermatitis which occurs either due to irritation or an allergic reaction to chemicals applied to the scalp may also cause itching

Semaglutide works through GLP-1 pathways involved in appetite, satiety, insulin release, and stomach emptying

The most commonly reported adverse drug reactions (ADRs) associated with GLP-1 therapies are gastrointestinal, including nausea, diarrhea, constipation, and vomiting